OSCR

Artificial Intelligence Algorithm Based on Genetics to Predict Responses to Interferon-Beta Treatment in Multiple Sclerosis Patients.

Overview

  1. Facultad de Informática, Universidad Autónoma de Querétaro, Querétaro 76230, Mexico; (A.M.H.-N.); (H.J.-H.); (J.A.A.-G.); (R.D.-P.)
  2. Facultad de Ingeniería, Universidad Autónoma de Querétaro, Querétaro 76010, Mexico; (J.D.M.-S.); (J.M.Á.-A.)
  3. Centro de Investigación en Tecnologías de Información y Sistemas, Universidad Autónoma del Estado de Hidalgo, Pachuca 42039, Mexico
  4. Centro de Ingeniería y Desarrollo Industrial, Querétaro 76125, Mexico
Journal: Bioengineering (Basel, Switzerland), volume 13, issue 5, article 523
Dates: received 18 March 2026; accepted 25 April 2026; published online 30 April 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.3390/bioengineering13050523 · PMID 42194280 · PMCID PMC13203318 · OpenAlex W7160028214
Open access: gold, a free copy (OpenAlex)
Categories: human (organism), multiple sclerosis (population), clinical / translational (subfield)
Methods: Machine learning, Statistics
Keywords: multiple sclerosis, machine learning, biomarkers, fuzzy system, genetic algorithm
Topic: Multiple Sclerosis Research Studies (Clinical Neurology, Medicine), according to OpenAlex
Funding: Secretaría de Ciencia, Humanidades, Tecnología e Innovación (331870)
Citations: not cited yet (Europe PMC); 64 references in the paper

Abstract

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) that impacts nearly 3 million people worldwide. While the etiology and pathogenesis of MS are not yet fully understood, current evidence suggests that it results from complex interactions between genetic and environmental conditions. Clarifying the autoimmune mechanisms underlying MS remains a central objective in the development of effective therapeutic strategies. Interferon-beta (IFN-β) is one of the most frequently prescribed disease-modifying treatments for individuals with MS. However, despite its established efficacy, recent studies report that approximately 30–50% of patients exhibit inadequate response to IFN-β, largely due to genetic variability. Machine learning (ML), a branch of artificial intelligence (AI), employs data-driven computational models to enhance predictive accuracy and classification. In recent MS research, unsupervised learning techniques such as hierarchical clustering and K-means have been applied for classification purposes. However, these methods often fail to yield optimal solutions because they require numerous arbitrary decisions and perform adequately only when datasets contain clusters of similar sizes and lack significant outliers. Fuzzy systems (FSs) are designed to model complex, ambiguous real-world phenomena. In this study, an AI algorithm incorporating a fuzzy system, informed by expert neurologist input, is proposed to enhance the assignment of unknown class labels related to IFN-β response in MS patients. Additionally, a genetic algorithm (GA) is introduced to identify optimal solutions within the search space, facilitating hyperparameter optimization of a deep learning (DL) model trained with genetic biomarkers to identify patients likely to benefit from this therapy. Experimental results demonstrate that the fuzzy system achieved 80% classification efficiency, in contrast to 64% with conventional hierarchical clustering. Furthermore, an artificial neural network (ANN) model, with hyperparameters optimized by the GA, achieved an accuracy of 0.8–1.0, surpassing the multi-layer perceptron (MLP), which achieved 0.6–0.8 accuracy using conventional tuning methods.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

The paper's code and data availability statement is in the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Other data links

Data Availability Statement

The collected gene expression data are available at https://github.com/eponcedeleon13-max/GSE24427_Gene_Expression_Data (accessed on 15 October 2025).

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 30 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 9 authors, 5 keywords, 1 funder, 51 references.

Cite

This paper

Ponce de León-Sánchez, E. R., Mendiola-Santibañez, J. D., Domínguez-Ramírez, O. A., Herrera-Navarro, A. M., Vázquez-Cervantes, A., Jiménez-Hernández, H., Acuña-García, J. A., Duarte-Pérez, R., & Álvarez-Alvarado, J. M. (2026). Artificial Intelligence Algorithm Based on Genetics to Predict Responses to Interferon-Beta Treatment in Multiple Sclerosis Patients. Bioengineering (Basel, Switzerland), 13(5), 523. https://doi.org/10.3390/bioengineering13050523

BibTeX

@article{poncedeleonsanchez2026artificial,
author = {Ponce de León-Sánchez, Edgar Rafael and Mendiola-Santibañez, Jorge Domingo and Domínguez-Ramírez, Omar Arturo and Herrera-Navarro, Ana Marcela and Vázquez-Cervantes, Alberto and Jiménez-Hernández, Hugo and Acuña-García, José Alfredo and Duarte-Pérez, Rafael and Álvarez-Alvarado, José Manuel},
title = {{Artificial Intelligence Algorithm Based on Genetics to Predict Responses to Interferon-Beta Treatment in Multiple Sclerosis Patients}},
journal = {Bioengineering (Basel, Switzerland)},
year = {2026},
month = apr,
volume = {13},
number = {5},
pages = {523},
publisher = {Multidisciplinary Digital Publishing Institute (MDPI)},
issn = {2306-5354},
doi = {10.3390/bioengineering13050523},
url = {https://doi.org/10.3390/bioengineering13050523},
pmid = {42194280},
pmcid = {PMC13203318}
}

RIS

TY - JOUR
AU - Ponce de León-Sánchez, Edgar Rafael
AU - Mendiola-Santibañez, Jorge Domingo
AU - Domínguez-Ramírez, Omar Arturo
AU - Herrera-Navarro, Ana Marcela
AU - Vázquez-Cervantes, Alberto
AU - Jiménez-Hernández, Hugo
AU - Acuña-García, José Alfredo
AU - Duarte-Pérez, Rafael
AU - Álvarez-Alvarado, José Manuel
TI - Artificial Intelligence Algorithm Based on Genetics to Predict Responses to Interferon-Beta Treatment in Multiple Sclerosis Patients
T2 - Bioengineering (Basel, Switzerland)
J2 - Bioengineering (Basel)
PY - 2026
DA - 2026/04/30
VL - 13
IS - 5
SP - 523
SN - 2306-5354
PB - Multidisciplinary Digital Publishing Institute (MDPI)
DO - 10.3390/bioengineering13050523
UR - https://doi.org/10.3390/bioengineering13050523
LA - en
ER -

CSL-JSON

{
"id": "10.3390/bioengineering13050523",
"type": "article-journal",
"title": "Artificial Intelligence Algorithm Based on Genetics to Predict Responses to Interferon-Beta Treatment in Multiple Sclerosis Patients",
"container-title": "Bioengineering (Basel, Switzerland)",
"author": [
{
"family": "Ponce de León-Sánchez",
"given": "Edgar Rafael"
},
{
"family": "Mendiola-Santibañez",
"given": "Jorge Domingo"
},
{
"family": "Domínguez-Ramírez",
"given": "Omar Arturo"
},
{
"family": "Herrera-Navarro",
"given": "Ana Marcela"
},
{
"family": "Vázquez-Cervantes",
"given": "Alberto"
},
{
"family": "Jiménez-Hernández",
"given": "Hugo"
},
{
"family": "Acuña-García",
"given": "José Alfredo"
},
{
"family": "Duarte-Pérez",
"given": "Rafael"
},
{
"family": "Álvarez-Alvarado",
"given": "José Manuel"
}
],
"container-title-short": "Bioengineering (Basel)",
"volume": "13",
"issue": "5",
"page": "523",
"DOI": "10.3390/bioengineering13050523",
"PMID": "42194280",
"PMCID": "PMC13203318",
"ISSN": "2306-5354",
"publisher": "Multidisciplinary Digital Publishing Institute (MDPI)",
"URL": "https://doi.org/10.3390/bioengineering13050523",
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
30
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.3390/mi14040749 [code]
A Deep Learning Approach for Predicting Multiple Sclerosis.
Journal: Micromachines
In common: multiple sclerosis, 12 references, 4 authors
[2] doi:10.1167/tvst.13.7.13 [code]
SLO-Net: Enhancing Multiple Sclerosis Diagnosis Beyond Optical Coherence Tomography Using Infrared Reflectance Scanning Laser Ophthalmoscopy Images.
Journal: Translational vision science & technology
In common: multiple sclerosis, clinical / translational, 2 references
[3] doi:10.1007/s13365-024-01208-9
Human endogenous retrovirus W in multiple sclerosis: transcriptional activity is associated with decline in oligodendrocyte proportions in the white matter of the brain.
Journal: Journal of neurovirology
In common: multiple sclerosis, 2 references
[4] doi:10.1186/s10194-025-02143-8
Artificial intelligence in headache medicine: between automation and the doctor-patient relationship. A systematic review.
Journal: The journal of headache and pain
In common: clinical / translational, 2 references
[5] doi:10.1111/jon.12977 [code]
Cortical and white matter lesion topology influences focal corpus callosum atrophy in multiple sclerosis.
Journal: Journal of neuroimaging : official journal of the American Society of Neuroimaging
In common: multiple sclerosis, clinical / translational, 1 reference
[6] doi:10.1155/bmri/5726771
Deep Learning Approaches for Multiple Sclerosis Detection in MRI Images.
Journal: BioMed research international
In common: multiple sclerosis, clinical / translational, 1 reference
[7] doi:10.3390/ijms231810651
Evaluation of Disability Progression in Multiple Sclerosis via Magnetic-Resonance-Based Deep Learning Techniques.
Journal: International journal of molecular sciences
In common: multiple sclerosis, clinical / translational, 1 reference
[8] doi:10.1162/imag.a.932 [code]
Automated segmentation of multiple sclerosis lesions, paramagnetic rims, and central vein sign on MRI provides reliable diagnostic biomarkers.
Journal: Imaging neuroscience (Cambridge, Mass.)
In common: multiple sclerosis, clinical / translational, 1 reference
[9] doi:10.1016/j.reth.2022.07.003
Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis.
Journal: Regenerative therapy
In common: multiple sclerosis, clinical / translational, 1 reference
[10] doi:10.1016/j.heliyon.2023.e15754
Association between vitamin D deficiency and multiple sclerosis- MRI significance: A scoping review.
Journal: Heliyon
In common: multiple sclerosis, clinical / translational, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.